Cargando…
A functional role of LEFTY during progesterone therapy for endometrial carcinoma
BACKGROUND: The left-right determination factor (LEFTY) is a novel member of the TGF-β/Smad2 pathway and belongs to the premenstrual/menstrual repertoire in human endometrium, but little is known about its functional role in endometrial carcinomas (Em Cas). Herein, we focused on LEFTY expression and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740891/ https://www.ncbi.nlm.nih.gov/pubmed/29268772 http://dx.doi.org/10.1186/s12964-017-0211-0 |
_version_ | 1783288101247909888 |
---|---|
author | Fei, Wu Kijima, Daiki Hashimoto, Mami Hashimura, Miki Oguri, Yasuko Kajita, Sabine Matsumoto, Toshihide Yokoi, Ako Saegusa, Makoto |
author_facet | Fei, Wu Kijima, Daiki Hashimoto, Mami Hashimura, Miki Oguri, Yasuko Kajita, Sabine Matsumoto, Toshihide Yokoi, Ako Saegusa, Makoto |
author_sort | Fei, Wu |
collection | PubMed |
description | BACKGROUND: The left-right determination factor (LEFTY) is a novel member of the TGF-β/Smad2 pathway and belongs to the premenstrual/menstrual repertoire in human endometrium, but little is known about its functional role in endometrial carcinomas (Em Cas). Herein, we focused on LEFTY expression and its association with progesterone therapy in Em Cas. METHODS: Regulation and function of LEFTY, as well as its associated molecules including Smad2, ovarian hormone receptors, GSK-3β, and cell cycle-related factors, were assessed using clinical samples and cell lines of Em Cas. RESULTS: In clinical samples, LEFTY expression was positively correlated with estrogen receptor-α, but not progesterone receptor (PR), status, and was inversely related to phosphorylated (p) Smad2, cyclin A2, and Ki-67 levels. During progesterone therapy, expression of LEFTY, pSmad2, and pGSK-3β showed stepwise increases, with significant correlations to morphological changes toward secretory features and decreased Ki-67 values. In Ishikawa cells, an Em Ca cell line that expresses PR, progesterone treatment reduced proliferation and induced increased expression of LEFTY and pGSK-3β, although LEFTY promoter regions were inhibited by transfection of PR. Moreover, inhibition of GSK-3β resulted in increased LEFTY expression through a decrease in its ubiquitinated form, suggesting posttranslational regulation of LEFTY protein via GSK-3β suppression in response to progesterone. In addition, overexpression or knockdown of LEFTY led to suppression or enhancement of Smad2-dependent cyclin A2 expression, respectively. CONCLUSION: Upregulation of LEFTY may serve as a useful clinical marker for the therapeutic effects of progesterone for Em Cas, leading to inhibition of tumor cell proliferation through alteration in Smad2-dependent transcription of cyclin A2. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12964-017-0211-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5740891 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57408912018-01-03 A functional role of LEFTY during progesterone therapy for endometrial carcinoma Fei, Wu Kijima, Daiki Hashimoto, Mami Hashimura, Miki Oguri, Yasuko Kajita, Sabine Matsumoto, Toshihide Yokoi, Ako Saegusa, Makoto Cell Commun Signal Research BACKGROUND: The left-right determination factor (LEFTY) is a novel member of the TGF-β/Smad2 pathway and belongs to the premenstrual/menstrual repertoire in human endometrium, but little is known about its functional role in endometrial carcinomas (Em Cas). Herein, we focused on LEFTY expression and its association with progesterone therapy in Em Cas. METHODS: Regulation and function of LEFTY, as well as its associated molecules including Smad2, ovarian hormone receptors, GSK-3β, and cell cycle-related factors, were assessed using clinical samples and cell lines of Em Cas. RESULTS: In clinical samples, LEFTY expression was positively correlated with estrogen receptor-α, but not progesterone receptor (PR), status, and was inversely related to phosphorylated (p) Smad2, cyclin A2, and Ki-67 levels. During progesterone therapy, expression of LEFTY, pSmad2, and pGSK-3β showed stepwise increases, with significant correlations to morphological changes toward secretory features and decreased Ki-67 values. In Ishikawa cells, an Em Ca cell line that expresses PR, progesterone treatment reduced proliferation and induced increased expression of LEFTY and pGSK-3β, although LEFTY promoter regions were inhibited by transfection of PR. Moreover, inhibition of GSK-3β resulted in increased LEFTY expression through a decrease in its ubiquitinated form, suggesting posttranslational regulation of LEFTY protein via GSK-3β suppression in response to progesterone. In addition, overexpression or knockdown of LEFTY led to suppression or enhancement of Smad2-dependent cyclin A2 expression, respectively. CONCLUSION: Upregulation of LEFTY may serve as a useful clinical marker for the therapeutic effects of progesterone for Em Cas, leading to inhibition of tumor cell proliferation through alteration in Smad2-dependent transcription of cyclin A2. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12964-017-0211-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-12-21 /pmc/articles/PMC5740891/ /pubmed/29268772 http://dx.doi.org/10.1186/s12964-017-0211-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Fei, Wu Kijima, Daiki Hashimoto, Mami Hashimura, Miki Oguri, Yasuko Kajita, Sabine Matsumoto, Toshihide Yokoi, Ako Saegusa, Makoto A functional role of LEFTY during progesterone therapy for endometrial carcinoma |
title | A functional role of LEFTY during progesterone therapy for endometrial carcinoma |
title_full | A functional role of LEFTY during progesterone therapy for endometrial carcinoma |
title_fullStr | A functional role of LEFTY during progesterone therapy for endometrial carcinoma |
title_full_unstemmed | A functional role of LEFTY during progesterone therapy for endometrial carcinoma |
title_short | A functional role of LEFTY during progesterone therapy for endometrial carcinoma |
title_sort | functional role of lefty during progesterone therapy for endometrial carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5740891/ https://www.ncbi.nlm.nih.gov/pubmed/29268772 http://dx.doi.org/10.1186/s12964-017-0211-0 |
work_keys_str_mv | AT feiwu afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT kijimadaiki afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT hashimotomami afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT hashimuramiki afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT oguriyasuko afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT kajitasabine afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT matsumototoshihide afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT yokoiako afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT saegusamakoto afunctionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT feiwu functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT kijimadaiki functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT hashimotomami functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT hashimuramiki functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT oguriyasuko functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT kajitasabine functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT matsumototoshihide functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT yokoiako functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma AT saegusamakoto functionalroleofleftyduringprogesteronetherapyforendometrialcarcinoma |